Codice QR

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases

Abstract Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast cancer. The main reason is the limited drug passage of the blood-brain barrier after...

Descrizione completa

Salvato in:
Autori principali: Eurydice Angeli, Justine Paris, Olivier Le Tilly, Céline Desvignes, Guillaume Gapihan, Didier Boquet, Frédéric Pamoukdjian, Diaddin Hamdan, Marthe Rigal, Florence Poirier, Didier Lutomski, Feriel Azibani, Alexandre Mebazaa, Amaury Herbet, Aloïse Mabondzo, Géraldine Falgarone, Anne Janin, Gilles Paintaud, Guilhem Bousquet
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMC 2024-04-01
Serie:Experimental Hematology & Oncology
Soggetti:
HER2 breast cancer
Brain metastases
Fab
Trastuzumab
Pharmacokinetic
Accesso online:https://doi.org/10.1186/s40164-024-00513-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi